Is neutrophil gelatinase-associated lipocalin unaffected by convective continuous renal replacement therapy? Definitely … maybe

Patrick M. Honore*, Rita Jacobs, Inne Hendrickx, Elisabeth De Waele, Viola Van Gorp and Herbert D. Spapen

See related research by Schilder et al., http://www.ccforum.com/content/18/2/R78; and Vasileiadis et al., http://www.ccforum.com/content/19/1/140

Two recent studies published in Critical Care reported that plasma [1] and urinary [2] levels of neutrophil gelatinase-associated lipocalin (NGAL), an important biomarker for prediction and diagnosis of acute kidney injury, were not affected by continuous renal replacement therapy (CRRT).

The investigators assessed NGAL elimination during continuous venovenous hemofiltration [1] and hemodiafiltration [2] using respectively a cellulose triacetate [1] and a polysulfone [2] membrane filter. Of note is that these filters both have notoriously low adsorption capacity [3]. Recently, the proinflammatory high-mobility group box 1 protein, a cytokine with a molecular weight approximating that of NGAL, was also found to be unaffected by convective CRRT. However, it was significantly (up to 90 %!) cleared from the circulation when highly adsorptive membranes (i.e., surface-treated acrylonitrile 69 and polymethylmethacrylate) were used [4].

These membranes are increasingly applied for hemofiltration in critically ill patients [4]. Thus, it is imperative to evaluate NGAL clearance during convective CRRT performed with highly adsorptive membranes before definitively accepting that CRRT leaves the sensitivity of this biomarker intact.

Abbreviations
CRRT: Continuous renal replacement therapy; NGAL: Neutrophil gelatinase-associated lipocalin.

Competing interests
The authors declare that they have no competing interests.

Published online: 17 November 2015

References